Results 101 to 110 of about 1,417,283 (133)

Neurotransmitter Systems in Alzheimer's Disease. [PDF]

Curr Issues Mol Biol
Ramírez-Expósito MJ, Cueto-Ureña C, Martínez-Martos JM.   +2 more
europepmc   +1 more source

Adenosine receptors and acute kidney injury: perspectives for future therapy. [PDF]

Purinergic Signal
Wissmann IB, Coelho RCD, Baseggio L, Cardoso AM.   +3 more
europepmc   +1 more source

P2Y14 receptor activation and neutrophil signaling: linking inflammation to systemic pathophysiology. [PDF]

Purinergic Signal
da Silva Ebone R, Doleski PH, Jantsch MH, da Silveira RP, Leal DBR.   +4 more
europepmc   +1 more source

Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination. [PDF]

PLoS One
De Herdt D, Lefevere E, Brouwers V, Hartvig L, Geeraerts E, Hsiao CC, Chen JQA, Pinto R, Duvey G, Burbidge S, Harmeier A, Knuesel I.   +11 more
europepmc   +1 more source

P2X7 receptor-dependent microglia-astrocyte coupling in Alzheimer's disease: from eATP sensing to synaptic and proteostatic failure. [PDF]

Front Aging Neurosci
Li Y, Liu S, Lan J.
europepmc   +1 more source

Ectonucleotidases and purinergic receptors in mouse prostate gland. [PDF]

Am J Clin Exp Urol
Yu J, Sharkey C, Olumi AF, Wang Z.
europepmc   +1 more source

Editorial: Purinergic signaling in metabolic diseases and inflammation pharmacology. [PDF]

Front Pharmacol
Sánchez-Melgar A, Sanz JM, Giuliani AL.
europepmc   +1 more source

Differential Effect of P2X7 Receptors on Proliferation and Migration of Human Keratinocytes and Dermal Fibroblasts. [PDF]

Int J Mol Sci
Soszyńska M, Komorowski M, Łuszczyński K, Radziszewski M, Krześniak N, Shevchenko K, Górecki DC, Malejczyk J, Ścieżyńska A.   +8 more
europepmc   +1 more source

The role of purinergic P2X3 receptors and endometriosis-associated hyperalgesia. [PDF]

Purinergic Signal
Pretto KP, de Souza Matias L, de Oliveira BD, Soares AA, Puntel CF, da Rocha Ricardo YA, Scheibel YT, de Resende E Silva DT.   +7 more
europepmc   +1 more source

Exocytosed ATP as a therapeutic target for inflammatory and metabolic diseases. [PDF]

Front Pharmacol
Hasuzawa N, Nomura S, Moriyama S, Moriyama Y, Nomura M.   +4 more
europepmc   +1 more source